Clinical trial · Interventional
First Line Chemotherapy for Advanced Cancer
Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma
NCT01980810CI-TRIAL-00022577GC-A-003terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): recruit too slowly
Summary
Brief summary (as posted)
The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| albumin-bounded paclitaxel | Drug | — | UNRESOLVED |
| S-1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- albumin-bounded paclitaxel plus S-1
- description
- arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
- interventionNames
- Drug: albumin-bounded paclitaxel
- Drug: S-1
Primary outcomes (1)
- measure
- response rate
- timeFrame
- 12 weeks
Secondary outcomes (3)
- measure
- progression free survival
- timeFrame
- 1 year
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Inoperable locally advanced, recurrent, and/or metastatic adenocarcinoma of the stomach or gastro-esophageal junction * Adult patients \>=18 years of age * Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2; * At least have one measurable disease(according to RECIST) * Adequate bone marrow,renal and liver function Exclusion Criteria: * Previous chemotherapy for advanced/metastatic disease * Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome
References
Publications (0)
Data not yet available
No reference posted for this study.